Sector News

Ferring hires former Boehringer exec as CMO

October 4, 2017
Life sciences

Privately-held Swiss drugmaker Ferring Pharmaceuticals has appointed Professor Klaus Dugi as executive vice president and chief medical officer (CMO), effective immediately.

He will be responsible for global medical affairs, quality assurance and pharmacovigilance. In addition, he will also be a member of the Ferring executive board.

Prior to this role, Prof Dugi held various leadership roles at Germany’s Boehringer Ingelheim, including vice president global medical affairs, CMO, and, most recently, managing director UK & Ireland.

“Making the industry more patient-centric has always been a top priority for Prof Dugi, and this is perfectly aligned with our company philosophy and commitment to solving unmet patient needs, particularly in the area of reproductive and maternal health,” said Michel Pettigrew, president of the executive board and chief operating officer, Ferring Pharmaceuticals.

A Professor of Medicine, with a speciality in internal medicine, Prof Dugi continues to teach medicine at Heidelberg University, Germany. He also spent four years carrying out research at the US National Institutes of Health (NIH) and has published more than 70 manuscripts in peer-reviewed journals including The Lancet and Diabetes.

Source: The Pharma Letter

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.